These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
859 related articles for article (PubMed ID: 26109617)
1. Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients. Goldrat O; Gervy C; Englert Y; Delbaere A; Demeestere I Hum Reprod; 2015 Sep; 30(9):2184-9. PubMed ID: 26109617 [TBL] [Abstract][Full Text] [Related]
2. Daily low-dose hCG stimulation during the luteal phase combined with GnRHa triggered IVF cycles without exogenous progesterone: a proof of concept trial. Andersen CY; Elbaek HO; Alsbjerg B; Laursen RJ; Povlsen BB; Thomsen L; Humaidan P Hum Reprod; 2015 Oct; 30(10):2387-95. PubMed ID: 26209535 [TBL] [Abstract][Full Text] [Related]
3. Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI. Mohsen IA; El Din RE Gynecol Endocrinol; 2013 Feb; 29(2):105-8. PubMed ID: 23134528 [TBL] [Abstract][Full Text] [Related]
4. IVF characteristics and the molecular luteal features of random start IVF cycles are not different from conventional cycles in cancer patients. Esmaeilian Y; Hela F; Bildik G; Akin N; İltumur E; Yusufoglu S; Yildiz CS; Keles İ; Vatansever D; Taskiran C; Yakin K; Oktem O Hum Reprod; 2023 Jan; 38(1):113-124. PubMed ID: 36367834 [TBL] [Abstract][Full Text] [Related]
5. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285 [TBL] [Abstract][Full Text] [Related]
6. Luteal granulosa cells from natural cycles are more capable of maintaining their viability, steroidogenic activity and LH receptor expression than those of stimulated IVF cycles. Bildik G; Akin N; Seyhan A; Esmaeilian Y; Yakin K; Keles I; Balaban B; Ata B; Urman B; Oktem O Hum Reprod; 2019 Feb; 34(2):345-355. PubMed ID: 30520979 [TBL] [Abstract][Full Text] [Related]
7. Fertility preservation for women with breast cancer: a multicentre randomized controlled trial on various ovarian stimulation protocols. Balkenende EME; Dahhan T; Beerendonk CCM; Fleischer K; Stoop D; Bos AME; Lambalk CB; Schats R; Smeenk JMJ; Louwé LA; Cantineau AEP; de Bruin JP; Linn SC; van der Veen F; van Wely M; Goddijn M Hum Reprod; 2022 Jul; 37(8):1786-1794. PubMed ID: 35776109 [TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: a systematic review. Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA Hum Reprod; 2017 May; 32(5):1033-1045. PubMed ID: 28333356 [TBL] [Abstract][Full Text] [Related]
9. Initiation of ovarian stimulation independent of the menstrual cycle: a case-control study. Buendgen NK; Schultze-Mosgau A; Cordes T; Diedrich K; Griesinger G Arch Gynecol Obstet; 2013 Oct; 288(4):901-4. PubMed ID: 23545834 [TBL] [Abstract][Full Text] [Related]
10. Towards an optimal luteal support modality in agonist triggered cycles: a randomized clinical trial. Elgindy EA; Sibai H; Mostafa MI; Gibreel A; Darwish E; Maghraby H Hum Reprod; 2018 Jun; 33(6):1079-1086. PubMed ID: 29562260 [TBL] [Abstract][Full Text] [Related]
11. The case for aromatase inhibitors use in oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in breast cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate. Fatum M; McVeigh E; Child T Hum Fertil (Camb); 2013 Dec; 16(4):235-40. PubMed ID: 23863119 [TBL] [Abstract][Full Text] [Related]
12. The comparision of effect of microdose GnRH-a flare-up, GnRH antagonist/aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients. Ozcan Cenksoy P; Ficicioglu C; Kizilkale O; Suhha Bostanci M; Bakacak M; Yesiladali M; Kaspar C Gynecol Endocrinol; 2014 Jul; 30(7):485-9. PubMed ID: 24592985 [TBL] [Abstract][Full Text] [Related]
13. Suboptimal response to GnRH-agonist trigger during oocyte cryopreservation: a case series. Russo M; Liu K; Chan C Reprod Biol Endocrinol; 2020 Jun; 18(1):59. PubMed ID: 32503566 [TBL] [Abstract][Full Text] [Related]
14. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846 [TBL] [Abstract][Full Text] [Related]
15. GnRH antagonist and letrozole co-treatment in diminished ovarian reserve patients: a proof-of-concept study. Olgan S; Humaidan P Reprod Biol; 2017 Mar; 17(1):105-110. PubMed ID: 28173995 [TBL] [Abstract][Full Text] [Related]
16. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582 [TBL] [Abstract][Full Text] [Related]
17. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles. Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004 [TBL] [Abstract][Full Text] [Related]
18. Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger? Lalami I; Labrosse J; Cedrin-Durnerin I; Comtet M; Vinolas C; Krief F; Sifer C; Peigne M; Grynberg M Reprod Biol Endocrinol; 2022 Jun; 20(1):87. PubMed ID: 35690817 [TBL] [Abstract][Full Text] [Related]
19. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Meirow D; Raanani H; Maman E; Paluch-Shimon S; Shapira M; Cohen Y; Kuchuk I; Hourvitz A; Levron J; Mozer-Mendel M; Brengauz M; Biderman H; Manela D; Catane R; Dor J; Orvieto R; Kaufman B Fertil Steril; 2014 Aug; 102(2):488-495.e3. PubMed ID: 24934489 [TBL] [Abstract][Full Text] [Related]
20. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. Oktay K; Hourvitz A; Sahin G; Oktem O; Safro B; Cil A; Bang H J Clin Endocrinol Metab; 2006 Oct; 91(10):3885-90. PubMed ID: 16882752 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]